- Home
- IVP vs EYEN Comparison
IVP vs EYEN Comparison
Compare IVP & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVP
- EYEN
- Stock Information
- Founded
- IVP 2020
- EYEN 2014
- Country
- IVP United States
- EYEN United States
- Employees
- IVP N/A
- EYEN N/A
- Industry
- IVP Diversified Commercial Services
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- IVP Miscellaneous
- EYEN Health Care
- Exchange
- IVP Nasdaq
- EYEN Nasdaq
- Market Cap
- IVP 3.3M
- EYEN 2.9M
- IPO Year
- IVP 2023
- EYEN 2018
- Fundamental
- Price
- IVP $1.66
- EYEN $11.93
- Analyst Decision
- IVP
- EYEN Hold
- Analyst Count
- IVP 0
- EYEN 4
- Target Price
- IVP N/A
- EYEN $2.00
- AVG Volume (30 Days)
- IVP 76.0K
- EYEN 9.8M
- Earning Date
- IVP 08-13-2025
- EYEN 08-11-2025
- Dividend Yield
- IVP N/A
- EYEN N/A
- EPS Growth
- IVP N/A
- EYEN N/A
- EPS
- IVP N/A
- EYEN N/A
- Revenue
- IVP $15,399,751.00
- EYEN $67,063.00
- Revenue This Year
- IVP N/A
- EYEN $7,680.45
- Revenue Next Year
- IVP N/A
- EYEN $315.38
- P/E Ratio
- IVP N/A
- EYEN N/A
- Revenue Growth
- IVP N/A
- EYEN 663.82
- 52 Week Low
- IVP $1.26
- EYEN $0.85
- 52 Week High
- IVP $401.50
- EYEN $124.80
- Technical
- Relative Strength Index (RSI)
- IVP 46.82
- EYEN 69.20
- Support Level
- IVP $1.51
- EYEN $3.68
- Resistance Level
- IVP $1.76
- EYEN $11.40
- Average True Range (ATR)
- IVP 0.13
- EYEN 2.03
- MACD
- IVP -0.02
- EYEN 0.58
- Stochastic Oscillator
- IVP 18.43
- EYEN 73.25
About IVP Inspire Veterinary Partners Inc.
Inspire Veterinary Partners Inc owns and operates veterinary hospitals throughout the United States. The company specializes in small animal general practice hospitals that serve all manner of companion pets, emphasizing canine and feline breeds.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.